{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T03:40:23Z","timestamp":1685504423030},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T00:00:00Z","timestamp":1268956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s12098-010-0052-y","type":"journal-article","created":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T12:25:05Z","timestamp":1269001505000},"page":"397-402","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of levels of antiretroviral drugs with efficacy in children with HIV infection"],"prefix":"10.1007","volume":"77","author":[{"given":"Ana Pilar","family":"Nso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Larru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ma","family":"Bell\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Jos\u00e9","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Tom\u00e1s","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Isabel","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"de Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,19]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0213-005X(05)75161-2","volume":"23","author":"E. Ribera","year":"2005","unstructured":"Ribera E, Lopez-Cortes LF, Soriano V, Casado JL, Mallolas J. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation? Enferm Infecc Microbiol Clin 2005; 23: 55\u201367.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"52_CR2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/00002030-200007070-00005","volume":"14","author":"J. Durant","year":"2000","unstructured":"Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. Aids 2000; 14: 1333\u20131339.","journal-title":"Aids"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C. Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids 2001; 15: 71\u201375.","journal-title":"Aids"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1468-1293.2002.00108.x","volume":"3","author":"G. Gatti","year":"2002","unstructured":"Gatti G, Pontali E, Boni S, De Pascalis CR, Bassetti M, Bassetti D. The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children. HIV Med 2002; 3: 125\u2013128.","journal-title":"HIV Med"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00003088-200544090-00004","volume":"44","author":"P.L. Fraaij","year":"2005","unstructured":"Fraaij PL, van Kampen JJ, Burger DM, de Groot R. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinet 2005; 44: 935\u2013956.","journal-title":"Clin Pharmacokinet"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"J.M. Tanner","year":"1976","unstructured":"Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51: 170\u2013179.","journal-title":"Arch Dis Child"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0378-4347(01)00172-4","volume":"757","author":"M. Sarasa-Nacenta","year":"2001","unstructured":"Sarasa-Nacenta M, Lopez-Pua Y, Mallolas J, Blanco JL, Gatell JM, Carne X. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 757: 325\u2013332.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"52_CR8","first-page":"720","volume":"5","author":"M.I. Jose Gomez de","year":"2000","unstructured":"de Jose Gomez MI, Prada F. [Antiretroviral treatment compliance in HIV-infected children]. Acta Pediatrica Esp 2000; 5: 720\u2013725.","journal-title":"Acta Pediatrica Esp"},{"key":"52_CR9","unstructured":"Guidelines for the use of antiretroviral agents in pediatric HIV infection. http:\/\/aidsinfo.nih.gov\/contentfiles\/PediatricGuidelines.pdf , 2008."},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1128\/AAC.44.4.1029-1034.2000","volume":"44","author":"C.V. Fletcher","year":"2000","unstructured":"Fletcher CV, Brundage RC, Remmel RP et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44: 1029\u20131034.","journal-title":"Antimicrob Agents Chemother"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.inf.0000215242.70300.95","volume":"25","author":"K.M. Crommentuyn","year":"2006","unstructured":"Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathot RA, Huitema AD, Beijnen JH. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Pediatr Infect Dis J 2006; 25: 538\u2013543.","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl1","key":"52_CR12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200203001-00002","volume":"16","author":"D. Back","year":"2002","unstructured":"Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. Aids 2002;16Suppl 1: S5\u2013S37.","journal-title":"Aids"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00007691-200404000-00006","volume":"26","author":"P.L. Fraaij","year":"2004","unstructured":"Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV\/AIDS. Ther Drug Monit 2004; 26: 122\u2013126.","journal-title":"Ther Drug Monit"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00126334-200301010-00016","volume":"32","author":"J.M. Treluyer","year":"2003","unstructured":"Treluyer JM, Burgard M, Cazali N et al. Relationship between antiretroviral drug plasma concentrations and viral load in children. J Acquir Immune Defic Syndr 2003;32:112\u2013115.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1542\/peds.114.2.e235","volume":"114","author":"P. Taylor","year":"2004","unstructured":"Taylor P, Worrell C, Steinberg SM et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114: e235\u2013e242.","journal-title":"Pediatrics"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/00002030-200009290-00008","volume":"14","author":"D. Jaquet","year":"2000","unstructured":"Jaquet D, Levine M, Ortega-Rodriguez E et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. Aids 2000; 14: 2123\u20132128.","journal-title":"Aids"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1592\/phco.21.9.861.34555","volume":"21","author":"C.A. Wedekind","year":"2001","unstructured":"Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 2001; 21: 861\u2013866.","journal-title":"Pharmacotherapy"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/00002030-200112070-00009","volume":"15","author":"P. Brambilla","year":"2001","unstructured":"Brambilla P, Bricalli D, Sala N et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. Aids 2001; 15: 2415\u20132422.","journal-title":"Aids"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007691-200404000-00003","volume":"26","author":"S.J. Soldin","year":"2004","unstructured":"Soldin SJ, Rakhmanina NY, Spiegel HM, Sever JL. Therapeutic drug monitoring for patients with HIV infection: Children\u2019s National Medical Center, Washington DC experience. Ther Drug Monit 2004; 26: 107\u2013109.","journal-title":"Ther Drug Monit"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00126334-200207010-00004","volume":"30","author":"J.J. Cheseaux","year":"2002","unstructured":"Cheseaux JJ, Jotterand V, Aebi C et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002; 30: 288\u2013293.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/135965350400900105","volume":"9","author":"F. Gutierrez","year":"2004","unstructured":"Gutierrez F, Padilla S, Masia M et al. Changes in body fat composition after 1 year of salvage therapy with lopinavir\/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations. Antivir Ther 2004; 9: 105\u2013113.","journal-title":"Antivir Ther"},{"key":"52_CR22","first-page":"399","volume-title":"Paediatric pharmacology: toward evidence-based drug therapy","author":"J. Treluyer","year":"1998","unstructured":"Treluyer J, Rey E, Pons G. Pharmacokinetic principles in paediatric pharmacology: proof of differences beyond the neonatal period. In: Tindall B, ed. Paediatric pharmacology: toward evidence-based drug therapy. London: Koren G, Diav-Citrin O, 1998: 399\u2013418."},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.283.2.205","volume":"283","author":"D. Descamps","year":"2000","unstructured":"Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). Jama 2000; 283: 205\u2013211.","journal-title":"Jama"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-010-0052-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12098-010-0052-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-010-0052-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T03:05:59Z","timestamp":1685502359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12098-010-0052-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,19]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s12098-010-0052-y","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,19]]}}}